Lilly’s Kisunla Delivers Sustained and Growing Impact in Early Symptomatic Alzheimer’s Over Three Years
Lilly (Eli Lilly and Company) has announced results from the long-term extension (LTE) of its Phase 3 TRAILBLAZER-ALZ 2 study, revealing that patients treated with Kisunla (donanemab-azbt) experienced a continued slowing of cognitive decline over three years. This sustained benefit was significantly greater compared to an untreated external group from
